Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Predicting resistance to high-dose fluticasone in eosinophilic esophagitis

A study in August's issue of Gastroenterology evaluates the efficacy, dose reduction, and resistance to high-dose fluticasone in patients with eosinophilic esophagitis.

News image

Dr Marc Rothenberg and colleagues from Ohio, USA evaluated the efficacy and safety of high-dose swallowed fluticasone propionate, and dose reduction in patients with eosinophilic esophagitis.

The research team analyzed esophageal transcriptomes to identify mechanisms.

The researchers conducted a randomized, multisite, double-blind, placebo-controlled trial of daily 1760 mcg fluticasone propionate in participants age 330 years with active eosinophilic esophagitis.

The team reported that 28 participants received fluticasone propionate, and 14 participants received placebo.

After 3 months, participants given fluticasone propionate who were in complete remission received 880 mcg fluticasone propionate daily.

65% of subjects given fluticasone propionate were in complete remission after 3 months
Gastroenterology

Participants in the fluticasone propionate or placebo groups who were not in complete remission continued or started, respectively, 1760 mcg fluticasone propionate daily for 3 additional months.

The team's primary end point was histologic evidence for complete remission.

Secondary end points were partial remission, symptoms, compliance, esophageal gene expression, esophageal eosinophil count, and the relationship between clinical features and fluticason propionate responsiveness.

After 3 months, the team found that 65% of subjects given fluticasone propionate and no subjects given placebo were in complete remission.

The research team observed that 12% of those given fluticasone propionate, and 8% of those given placebo were in partial remission.

In the fluticasone propionate group, 73% of subjects remained in complete remission, and 20% were in partial remission after the daily dose was reduced by 50%.

Extending fluticasone propionate therapy in fluticasone propionate-resistant participants did not induce remission.

The researchers observed that fluticasone propionate decreased heartburn severity.

Compliance, age, sex, atopic status, or anthropomorphic features were not associated with response to fluticasone propionate.

Gene expression patterns in esophageal tissues of fluticasone propionate responders were similar to those of patients without EoE.

The researchers found evidence for heterogeneous steroid signaling in subjects who did not respond to fluticasone propionate, and preliminary evidence for transcripts predictive of fluticasone propionate responsiveness.

Dr Rothenberg's team commented, "Daily administration of a high dose of fluticasone propionate induces histologic remission in 65%77% of patients with eosinophilic esophagitis after 3 months."

"A 50% dose reduction remained effective in 73%93% of patients who initially responded to fluticasone propionate."

"Nonresponders had evidence of steroid resistance."

"Histologic and molecular markers may predict resistance."

Gastroenterol 2014: 147(2): 324333.e5
29 July 2014

Go to top of page Email this page Email this page to a colleague

 28 August 2015

Advanced search
 28 August 2015 
Statin use and survival in pancreatic cancer
 28 August 2015 
Bacterial endotoxin and NAFLD
 28 August 2015 
Interferon-free regimens for Hep C
 27 August 2015 
HCV in Egypt
 27 August 2015 
Gene expression for hepatocellular carcinoma
 27 August 2015 
Liver abnormalities in celiac disease
 26 August 2015 
Medical management of diverticular disease
 26 August 2015 
Treatment of erosive esophagitis
 26 August 2015 
Dermatological complications of anti-TNF therapy in IBD
 25 August 2015 
Markers for colorectal cancer screening
 25 August 2015 
Long-term PPI use and serum gastrin levels
 25 August 2015 
Treatment for HCV and HIV-1 co-infection
 24 August 2015 
Treatment for HCV and HIV-1 co-infection
 24 August 2015 
Cirrhosis in Hepatitis C patients
 24 August 2015 
Aspirin use and colorectal cancer survival
 21 August 2015 
Activity indexes in ulcerative colitis
 21 August 2015 
Coffee and gallstone disease
 21 August 2015 
Alcoholic cirrhosis in relapse after liver transplant
 20 August 2015 
Cirrhosis in the USA
 20 August 2015 
Mortality causes in liver cirrhosis
 20 August 2015 
Risk of death in IBD
 19 August 2015 
Predicting intestinal surgery in Crohn's disease
 19 August 2015 
Improved screening colonoscopy quality
 19 August 2015 
Sleep positioning device reduces reflux
 18 August 2015 
Health insurance influences HCV screening outcomes
 18 August 2015 
Somatostatin analogues in polycystic liver disease
 18 August 2015 
Global consensus report on H. pylori gastritis
 17 August 2015 
Biomarker of fibrosis stage in NAFLD
 17 August 2015 
Prognostic score for primary biliary cirrhosis
 17 August 2015 
Measuring subjective health in patients with IBS
 14 August 2015 
Factors that influence ulcerative colitis procedure type
 14 August 2015 
H. pylori in African American and Hispanic veterans
 14 August 2015 
Hep E virus in decompensated chronic liver disease
 13 August 2015 
H. pylori in drinking water
 13 August 2015 
Sofosbuvir-regimens in HCV
 13 August 2015 
IBS among Japanese adolescents
 12 August 2015 
Infliximab in patients in IBD
 12 August 2015 
Peritoneal carcinomatosis in colorectal cancer
 12 August 2015 
Predictors of severity of IBD
 11 August 2015 
H. pylori and immune thrombocytopenic purpura
 11 August 2015 
Chemotherapy and intestinal microbiomes
 11 August 2015 
Sexual dysfunction after rectal cancer treatment
 10 August 2015 
Scoring systems to predict alcoholic hepatitis outcomes
 10 August 2015 
Sofosbuvir-based regimens in veterans with HCV
 10 August 2015 
Predicting lymph node metastasis in T1 colorectal cancer
 07 August 2015 
Factors associated with changes in ulcerative colitis
 07 August 2015 
Bariatric surgery and NASH in obese patients
 07 August 2015 
Caffeine and fibrosis in Hep C
 06 August 2015 
Disparities in colonoscopic examination
 06 August 2015 
Weight loss and NASH
 06 August 2015 
Diagnosis of IBS
 05 August 2015 
Gender differences in fecal immunochemical tests
 05 August 2015 
Adenoma detection rates with a screening colonoscopy program
 05 August 2015 
Extraintestinal manifestations in IBD diagnosis
 04 August 2015 
IBD environmental risk factors
 04 August 2015 
Measuring disease activity in Crohn's
 04 August 2015 
Gastric emptying and hyperglycemia in diabetes
 03 August 2015 
Vaccinations and IBD
 03 August 2015 
Lack of response to therapy in severe ulcerative colitis
 03 August 2015 
Nutritional vs biological therapy in Crohn's

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us